In a move aimed at addressing the $20 billion global generic injectable hospital drug market, Piramal Enterprises on Tuesday said that it has entered into an agreement to acquire five anesthesia and pain management injectable products from Janssen Pharmaceutica NV. This is an all-cash deal for an upfront consideration of $155 million, and up to an additional $20 million.